公开(公告)号：US20100113338A1

公开(公告)日：2010-05-06

申请号：US11993580

申请日：2006-06-21

申请人： Masanao Watanabe ,  Kazuo Tsubota ,  Masaki Hirashima ,  Chikateru Nozaki

发明人： Masanao Watanabe ,  Kazuo Tsubota ,  Masaki Hirashima ,  Chikateru Nozaki

IPC分类号： A61K38/16 ,  C07K14/00 ,  A61P27/02

CPC分类号： A61K38/1761 ,  A61K9/0048

摘要： Disclosed is a novel composition for the treatment of a corneal/conjunctival disease. A prophylactic or therapeutic agent for a corneal/conjunctival disease comprising selenoprotein P as an active ingredient, more specifically a prophylactic or therapeutic agent for a corneal/conjunctival disease such as dry eye, keratoconjunctivitis sicca, superficial punctate keratopathy, corneal erosion or corneal ulcer comprising selenoprotein P as an active ingredient, particularly a prophylactic or therapeutic agent for a corneal/conjuncrtival disease such as dry eye, keratoconjunctivitis sicca, superficial punctate keratopathy, corneal erosion or corneal ulcer accompanied by a corneal/conjunctival epithelial discorder.

摘要翻译： 公开了用于治疗角膜/结膜疾病的新型组合物。 一种用于角膜/结膜疾病的预防或治疗剂，其包含硒蛋白P作为活性成分，更具体地，涉及用于角膜/结膜疾病如干眼症，圆锥形结膜炎丝氨酸，浅表性点状角膜病，角膜侵蚀或角膜溃疡的预防或治疗剂，其包括 硒蛋白P作为活性成分，特别是用于角膜/结膜性疾病例如干眼症，透角圆锥形结膜炎，浅表性点状角膜病变，伴随角膜/结膜上皮发生器的角膜侵蚀或角膜溃疡的预防或治疗剂。

公开(公告)号：US20100093010A1

公开(公告)日：2010-04-15

申请号：US12606792

申请日：2009-10-27

申请人： Yasuomi Urano ,  Takao Hamakubo ,  Tatsuhiko Kodama

发明人： Yasuomi Urano ,  Takao Hamakubo ,  Tatsuhiko Kodama

IPC分类号： C12Q1/37 ,  C12Q1/25 ,  C12Q1/26

CPC分类号： A61K31/22 ,  A61K31/366 ,  A61K31/401 ,  G01N2333/96425 ,  G01N2800/2821

摘要： It is intended to provide an inhibitor for the formation of a γ-secretase complex which comprises a cholesterol synthesis inhibitor or a protein geranylgeranylation regulator as the active ingredient; and use of a cholesterol synthesis inhibitor or a protein geranylgeranylation regulator for producing the same. It is also intended to provide a method of screening a substance having an effect of inhibiting the formation of an active complex of γ-secretase which comprises assaying the activity of inhibiting cholesterol synthesis or quantifying cholesterol accumulated in lipid rafts in cells. It is also intended to provide a method of screening a cholesterol synthesis inhibitor, a protein geranylgeranylation regulator or an HMG-CoA reductase inhibitor which comprises assaying the effect of inhibiting the formation of an active complex of γ-secretase. Moreover, it is intended to provide a method of screening an effect of a test substance on γ-secretase which comprises measuring the distribution of constituents (niscastrin, APH-1, Pen-2 and so on) required by γ-secretase for the formation of its active complex in cells.

摘要翻译： 旨在提供用于形成γ-分泌酶复合物的抑制剂，其包含胆固醇合成抑制剂或蛋白质香叶基香叶基化调节剂作为活性成分; 以及使用胆固醇合成抑制剂或蛋白质香叶基香叶基化调节剂来制备它们。 本发明还提供一种筛选具有抑制γ-分泌酶活性复合物形成的作用的物质的方法，该方法包括测定抑制胆固醇合成的活性或量化在细胞中积累的脂筏中的胆固醇。 本发明还旨在提供一种筛选胆固醇合成抑制剂，蛋白er牛儿基胆碱化调节剂或HMG-CoA还原酶抑制剂的方法，其包括测定抑制γ-分泌酶活性复合物形成的作用。 此外，旨在提供一种筛选测试物质对γ分泌酶的作用的方法，其包括测量γ-分泌酶对于形成所需的成分（脑膜炎，APH-1，Pen-2等）的分布 其活性复合物在细胞中。

公开(公告)号：US07695141B2

公开(公告)日：2010-04-13

申请号：US12283637

申请日：2008-09-12

申请人： Takuya Hara ,  Kazunori Matsumura ,  Tatsuya Fujii ,  Masaharu Mizuochi

发明人： Takuya Hara ,  Kazunori Matsumura ,  Tatsuya Fujii ,  Masaharu Mizuochi

IPC分类号： A61B3/10

CPC分类号： A61B5/0496

摘要： A stimulus light from a stimulus light source is projected to the retina of an ocular fundus under examination to stimulate the retina in localized fashion to generate a bioelectric signal from the retina. The stimulus light source is mounted on a movable block, and an operating lever is used to move the stimulus light source to change the stimulus light on the retina. The size of the stimulus light can also be varied using a panel having a plurality of openings with different diameters for allowing the stimulus light to pass through. This assures a reliable local ERG examination because the bioelectrical signal can be produced in a wider area of the retina. The operating lever is further fixed by inserting a cap to keep the projected stimulus light unchanged. This allows the burden on the examiner to be reduced remarkably, assuring a reliable local ERG examination.

摘要翻译： 来自刺激光源的刺激光被投射到正在检查的眼底视网膜，以局部方式刺激视网膜以从视网膜产生生物电信号。 刺激光源安装在可动块上，操作杆用于移动刺激光源以改变视网膜上的刺激光。 刺激光的尺寸也可以使用具有不同直径的多个开口的面板来改变，以允许刺激光通过。 这确保了可靠的局部ERG检查，因为生物电信号可以在视网膜的更广的区域中产生。 通过插入盖子来进一步固定操作杆，以保持投影的刺激光线不变。 这样可以显着降低审查员的负担，确保当地的ERG检查可靠。

公开(公告)号：US20100035927A1

公开(公告)日：2010-02-11

申请号：US12523436

申请日：2008-01-22

申请人： Kosei Ojika ,  Noriyuki Matsukawa

发明人： Kosei Ojika ,  Noriyuki Matsukawa

IPC分类号： A61K31/445 ,  A61P25/28

CPC分类号： A61K31/19 ,  A61K31/445 ,  A61K45/06 ,  A61K2300/00

摘要： A medicament for prophylactic and/or therapeutic treatment of Alzheimer-type dementia, which comprises donepezil hydrochloride and valproic acid or a salt thereof in combination.

摘要翻译： 一种用于预防和/或治疗阿尔茨海默氏型痴呆的药物，其包括盐酸多奈哌齐和其丙戊酸或其盐的组合。

公开(公告)号：US20100003312A1

公开(公告)日：2010-01-07

申请号：US12428663

申请日：2009-04-23

申请人： Makoto Kanebako ,  Gou Yanagimoto ,  Toru Watanabe ,  Shouichi Hasegawa

发明人： Makoto Kanebako ,  Gou Yanagimoto ,  Toru Watanabe ,  Shouichi Hasegawa

IPC分类号： A61K9/70 ,  A61K47/30 ,  A61P43/00

CPC分类号： A61K9/7061 ,  A61K9/7076

摘要： An object of the invention is to provide a hydrous external skin patch, which has adherence sufficient for adhering to an affected area for several times without using an auxiliary tape or the like and is excellent in utility so that the patch can be easily peeled off even if the paste adheres to itself before application to the affected area.The hydrous external skin patch is characterized in that a paste of the patch comprises 0.1 to 10 wt % of a drug, 0.1 to 20 wt % of an adhesive base, 0.001 to 3.0 wt % of a crosslinker, 15 to 60 wt % of water, 2 to 20 wt % of a tackifier resin, 0.4 to 10 wt % of a dissolving agent for the tackifier resin, 0.1 to 30 wt % of an oil absorbing inorganic powder, and 0.1 to 20 wt % of a dextrin fatty acid ester and has a thickness of 100 to 1,000 μm.

摘要翻译： 本发明的目的是提供一种含水的外用皮肤贴剂，其具有足以粘附到受影响区域上几次的粘附性，而不使用辅助带等，并且具有优异的效用，使得贴剂可以容易地剥离甚至 如果膏剂在应用于受影响的区域之前粘附于自身。 含水外皮肤的特征在于，贴剂的糊剂含有0.1〜10重量％的药物，0.1〜20重量％的粘合剂基质，0.001〜3.0重量％的交联剂，15〜60重量％的水 ，增粘树脂2〜20重量％，增粘树脂用溶解剂0.4〜10重量％，吸油性无机粉末0.1〜30重量％，糊精脂肪酸酯0.1〜20重量％，糊精 厚度为100〜1000μm。

公开(公告)号：US20090215703A1

公开(公告)日：2009-08-27

申请号：US11909931

申请日：2006-03-29

申请人： Hiroyuki Ishiwata ,  Mototsugu Kabeya ,  Toru Kanke

发明人： Hiroyuki Ishiwata ,  Mototsugu Kabeya ,  Toru Kanke

IPC分类号： A61K38/03 ,  C07K4/00 ,  A61P27/00

CPC分类号： C07K5/0812 ,  A61K38/00 ,  C07K5/101 ,  C07K5/1016

摘要： The present invention relates to a pharmaceutical composition for preventing/treating conditions associated with PAR-2. The present invention also relates to a method for preventing/treating the condition using the pharmaceutical composition and use for manufacturing the pharmaceutical composition. The pharmaceutical composition comprises a compound represented by the following general formula (1), salt or solvate thereof and a pharmaceutically acceptable carrier: Ar—CO-AA1-AA2-AA3-AA4-NH—X—Y (1) wherein, Ar represents a phenyl group or an aromatic heterocyclic group optionally having substituent(s): AA1 represents a hydrophobic amino acid: AA2 represents an amino acid absent of substituent (s) having more than two carbon atoms: AA3 represents an amino acid absent of substituent(s) having more than two carbon atoms: AA4 represents a basic amino acid: X represents a straight-chain or branched bivalent saturated aliphatic hydrocarbon group having 1 to 6 carbon atoms: Y represents basic substituent (s); straight-chain, branched, or cyclic bivalent saturated aliphatic hydrocarbon group having 1 to 6 carbon atoms, or an aromatic hydrocarbon group having 6 to 10 carbon atoms. The compound represented by the general formula (1) has dramatically improved PAR-2 activation potency compared to peptide comprised of 6 amino acids (Tethered receptor agonist peptide: TRAP) in spite of reduction of the number of amino acid.

摘要翻译： 本发明涉及用于预防/治疗与PAR-2相关的病症的药物组合物。 本发明还涉及使用药物组合物预防/治疗病症的方法以及用于制造药物组合物的方法。 药物组合物包含由以下通式（1）表示的化合物，其盐或溶剂化物和药学上可接受的载体：Ar-CO-AA1-AA2-AA3-AA4-NH-XY（1）其中Ar表示苯基 基团或任选具有取代基的芳族杂环基：AA1表示疏水性氨基酸：AA2表示不具有多于两个碳原子的取代基的氨基酸：AA3表示不具有取代基的氨基酸， 两个以上碳原子：AA4表示碱性氨基酸：X表示碳原子数1〜6的直链或支链二价饱和脂肪族烃基，Y表示碱性取代基。 具有1至6个碳原子的直链，支链或环状二价饱和脂族烃基或具有6至10个碳原子的芳族烃基。 尽管氨基酸数量的减少，但由通式（1）表示的化合物与包含6个氨基酸的肽（束缚受体激动剂肽：TRAP）相比，显着提高了PAR-2的活化效力。

公开(公告)号：US07553865B2

公开(公告)日：2009-06-30

申请号：US10521958

申请日：2003-07-22

申请人： Hiroyuki Shirai ,  Tatsuya Nakai ,  Masami Serizawa ,  Yasuo Shinoda ,  Toshio Inagi

发明人： Hiroyuki Shirai ,  Tatsuya Nakai ,  Masami Serizawa ,  Yasuo Shinoda ,  Toshio Inagi

IPC分类号： A61K31/40 ,  A01N43/38 ,  C07D209/26

CPC分类号： A61K9/06 ,  A61K9/0014 ,  A61K31/405 ,  A61K47/02 ,  A61K47/10 ,  A61K47/14 ,  A61K47/32 ,  A61K47/38 ,  A61K47/44

摘要： An object of the present invention is to provide an indomethacin external preparation that has an excellent use feeling and excellent absorbability and causes no phase separation into an oil layer and an aqueous layer, thus exhibiting satisfactory stability of preparation with time. Provided is an indomethacin external preparation containing: 0.1 to 3 wt % of indomethacin; 25 to 50 wt % of alcohol; 0.01 to 5 wt % of gelling agent; 5 to 30 wt % of oil component; 20 to 50 wt % of water; and 0.01 to 10 wt % of one or more components selected from the group consisting of glyceryl monostearate, sorbitan monostearate, stearyl alcohol, and polyethylene glycol monostearate.

摘要翻译： 本发明的目的是提供具有优异的使用感和优异的吸收性的吲哚美辛外用制剂，并且不会使相分离成油层和水层，从而表现出令人满意的制备时间稳定性。 本发明提供消炎痛外用制剂，含有0.1〜3重量％的吲哚美辛; 25〜50重量％的醇; 0.01〜5重量％的胶凝剂; 5〜30重量％的油成分; 20〜50重量％的水; 和0.01〜10重量％的选自单硬脂酸甘油酯，脱水山梨糖醇单硬脂酸酯，硬脂醇和聚乙二醇单硬脂酸酯的一种或多种成分。

公开(公告)号：USD594493S1

公开(公告)日：2009-06-16

申请号：US29287438

申请日：2007-08-08

申请人： Kennosuke Chujo ,  Ryouichi Sasaoka

设计人： Kennosuke Chujo ,  Ryouichi Sasaoka

公开(公告)号：US07538669B2

公开(公告)日：2009-05-26

申请号：US11497856

申请日：2006-08-01

申请人： Kazuhiro Kashiwagi ,  Hiroyuki Koide ,  Yasushi Kikukawa ,  Takao Shinohara

发明人： Kazuhiro Kashiwagi ,  Hiroyuki Koide ,  Yasushi Kikukawa ,  Takao Shinohara

IPC分类号： G08B1/08 ,  G08B29/00 ,  H04B17/00

CPC分类号： G08B25/10

摘要： A wireless sensor system according to the invention has a wireless sensor device for detecting something and a wireless base station for exchanging data with the wireless sensor device by wireless. The wireless sensor device 2 has a sampling signal transmitting portion for transmitting a sampling signal, and the wireless base station has a sensitivity detecting portion for detecting a receive sensitivity of the sampling signal, and a sensitivity transmitting portion for transmitting a result detected thereby to the wireless sensor device. And, the wireless sensor device has at least one of a LED and a buzzer for informing of the receive sensitivity on the basis of data from the sensitivity transmitting portion. A worker who tries to locate the wireless sensor device can easily know the best place for location with the LED or the like.

摘要翻译： 根据本发明的无线传感器系统具有用于检测物体的无线传感器装置和用于通过无线与无线传感器装置交换数据的无线基站。 无线传感器装置2具有用于发送采样信号的采样信号发送部，无线基站具有用于检测采样信号的接收灵敏度的灵敏度检测部，以及灵敏度发送部，将由此检测到的结果发送到 无线传感器设备。 并且，无线传感器装置具有LED和蜂鸣器中的至少一个，用于根据来自灵敏度发送部分的数据来通知接收灵敏度。 尝试找到无线传感器设备的工作人员可以很容易地知道使用LED等的最佳位置。

公开(公告)号：US20090043384A1

公开(公告)日：2009-02-12

申请号：US12088419

申请日：2006-09-22

申请人： Kazuharu Niwa ,  Atsushi Kobayashi ,  Kosuke Satake

发明人： Kazuharu Niwa ,  Atsushi Kobayashi ,  Kosuke Satake

IPC分类号： A61F2/16

CPC分类号： A61F2/1635 ,  A61F2/1648 ,  A61F2250/0018

摘要： An intraocular lens of novel structure exhibiting an excellent focus adjusting power. A hollow capsule structure is filled with a transparent liquid-like or gel-like filler (32). A front wall of the capsule structure is composed of a flexible lens front film (16), and a rear wall of the capsule structure is composed of an optical lens (18) having a diameter larger than that of the flexible lens front film (16). Under a state inserted into and attached to a capsula lentis, pressure variation of a corpus vitreum acts on the optical lens (18) to enable focal refraction power to be adjusted by utilizing swelling deformation of the lens front film (16).

摘要翻译： 具有优异的聚焦调节功率的新颖结构的眼内透镜。 中空胶囊结构填充有透明液体状或凝胶状填料（32）。 胶囊结构的前壁由柔性透镜前膜（16）构成，胶囊结构的后壁由直径大于柔性透镜前膜（16）的光学透镜（18）构成， ）。 在插入并附着于扁桃体的状态下，玻璃体的压力变化作用在光学透镜（18）上，以通过利用透镜前膜（16）的膨胀变形来调节聚焦折射力。